newsfilter
← Latest News
GlobeNewswire·

Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026

• Late-breaking poster will present data from the first-in-human Phase I study of IMP761, a first-in-class LAG-3 agonist antibody, in healthy volunteers SYDNEY, AUSTRALIA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Immutep